Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .
NEW YORK A U.S. administrative court on Wednesday invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.
NEW YORK, Jan 17 A U.S. administrative court on Wednesday invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.
Positive lung cancer results for Merck & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent.
NEW YORK Botox-maker Allergan Plc on Wednesday said it plans to cut over 1,000 jobs, more than 5 percent of its workforce, and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.
NEW YORK Drugmakers opened the new year by raising U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit in response to a backlash from consumers and politicians.
NEW YORK Hedge fund Brigade Capital Management, a top shareholder in Kindred Healthcare Inc , said on Wednesday the deal by U.S. health insurer Humana Inc and two private equity firms to buy Kindred was "disappointing and grossly inadequate."
Tenet Healthcare Corp on Tuesday said it is putting its Conifer unit up for sale and plans to cut $100 million more in costs, as its new chief executive works to slash its heavy debt load.
NEW YORK Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.
Valeant Pharmaceuticals International Inc reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye care business, sending its shares up more than 15 percent.
- Gold: PRECIOUS-Gold up, dollar shaken by U.S. government shutdown fears
- Oil Report: UPDATE 3-Jordan's king tells Pence U.S. must rebuild trust after Jerusalem decision
- British Pound Report: UPDATE 3-Sterling falls after weak retail sales numbers dent optimism
- US Dollar Report: FOREX-U.S. shutdown fears pressure dollar, mark worst run since 2015